The Test Group will be patients with rheumatoid arthritis, newly starting therapy with
etanercept (Enbrel). Inclusion criteria for the exposed cohort subjects are:
- Patients aged 18 years and over at the time of diagnosis;
- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);
- Patients who have given informed consent for long term follow-up and access to all
medical records;
- Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel)
for RA.
The Control Group:
- Patients aged 18 years and over a the time of diagnosis;
- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);
- Patients who have given informed consent for long term follow-up and access to all
medical records; Patients are receiving at least one traditional DMARD and have never
been prescribed a biologic agent;
Per BSRBR registry since data is retropsectively being analyzed